Sign In
Buy SENS
$5.03
-0.0400 (-0.789%)
At Close: Jul 31, 2026
GERMANTOWN, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable
GERMANTOWN, Md., May 21, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable
Revisiting Senseonics After 4 Years: Still A Big Investment Opportunity
03:35am, Wednesday, 21'st May 2025
I share my recent interview with Senseonics CEO, Tim Goodnow and the CFO, Rick Sullivan. Senseonics has recently introduced a 365-day Continuous Glucose Monitoring system, aiming to disrupt a market d
Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement
11:12pm, Thursday, 15'th May 2025
GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable c
Senseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private Placement
04:05pm, Thursday, 15'th May 2025
GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable c
Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates
08:05pm, Thursday, 08'th May 2025
Senseonics Holdings (SENS) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.
Senseonics Holdings, Inc. (SENS) Q1 2025 Earnings Call Transcript
07:55pm, Thursday, 08'th May 2025
Senseonics Holdings, Inc. (NYSE:SENS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations, LifeSci Advisors Tim Goodnow - President and Chi
GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable
twiist™ expands compatibility offerings to become the first AID system compatible with Senseonics Eversense® 365 one-year CGM system
Senseonics (SENS) Upgraded to Buy: What Does It Mean for the Stock?
01:06pm, Thursday, 06'th Mar 2025
Senseonics (SENS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Senseonics Holdings, Inc. (SENS) Q4 2024 Earnings Call Transcript
06:29pm, Monday, 03'rd Mar 2025
Senseonics Holdings, Inc. (NYSE:SENS ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations, LifeSci Advisors Tim Goodnow - President and C
Senseonics Holdings (SENS) Reports Q4 Loss
06:15pm, Monday, 03'rd Mar 2025
Senseonics Holdings (SENS) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.03 per share a year ago.
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
04:05pm, Monday, 03'rd Mar 2025
Received FDA approval for Eversense ® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia
Eversense 365 and SweetSpot Integrate Software to Optimize Diabetes Care
07:30am, Wednesday, 26'th Feb 2025
Senseonics and Ascensia integrate software between SweetSpot and Eversense 365, the world's first and only One Year CGM system
Senseonics Holdings, Inc. to Participate in the TD Cowen 45th Annual Health Care Conference
04:05pm, Thursday, 13'th Feb 2025
GERMANTOWN, Md., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable
